10-Q: STAAR Surgical Reports Strong Q1 2026 Results Driven by China Growth

STAAR Surgical Company announced a significant increase in net sales and a return to profitability in the first quarter of 2026, largely driven by robust performance in China.

Summary

• STAAR Surgical Company reported a substantial increase in net sales for the first quarter of 2026, reaching $93.5 million, a 119.6% rise compared to $42.6 million in the same period of 2025.
• The company returned to profitability with a net income of $5.2 million ($0.10 per diluted share) in Q1 2026, a significant improvement from a net loss of $54.2 million ($1.10 per diluted share) in Q1 2025.
• Gross profit margin improved to 73.6% from 65.8% year-over-year, attributed to cost reduction initiatives and improved manufacturing efficiencies.
• General and administrative, selling and marketing, and research and development expenses all decreased as a percentage of sales compared to the prior year quarter.
• The company incurred $6.7 million in merger transaction and related costs in Q1 2026, related to the terminated merger with Alcon and the Cooperation Agreement.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to the significant revenue growth, return to profitability, and improved margins, despite some ongoing costs and a decrease in cash reserves.

Positives

• Net sales surged by 119.6% to $93.5 million in Q1 2026, driven by strong performance in China.
• The company achieved profitability with a net income of $5.2 million, a significant turnaround from a net loss in the prior year.
• Gross profit margin improved to 73.6% from 65.8%, reflecting successful cost reduction and manufacturing efficiency efforts.
• Significant sales growth in the APAC region (218%), particularly in China, Japan, and Korea.
• The launch of EVO+ ICL in China was well-received, supporting potential margin expansion.
• Operating expenses as a percentage of sales decreased across general and administrative, selling and marketing, and research and development categories.

Negatives

• Cash and cash equivalents decreased by $21.3 million to $131.9 million, and total cash and investments available for sale decreased by $23.6 million to $163.9 million.
• The company incurred $6.7 million in merger transaction and related costs.
• The company experienced foreign exchange losses of $1.1 million in Q1 2026.
• There was an impairment on leasehold improvements and machinery and equipment of $7.1 million, and on real property right-of-use assets of $3.4 million, and on internally developed software of $2.8 million in the prior year quarter (Q1 2025).

Risks

• Reliance on independent distributors in international markets.
• Potential slowdown or disruption in the Chinese economy.
• Global economic conditions and international trade disputes, including tariffs.
• Fluctuations in foreign currency exchange rates.
• Competition in the ophthalmic surgical product market.
• Potential losses due to product liability claims.
• Exposure to environmental liability.
• Data corruption, cyber-based attacks, or network security breaches.
• Extensive clinical trials and resources devoted to research and development.
• Compliance with government regulations and potential changes in FDA or international regulations.
• Product recalls or failures.

Future Outlook

The company expects to generate cash during the remainder of the year and believes its sources of liquidity will be sufficient to meet anticipated cash needs for at least 12 months. By the end of fiscal 2026, the company expects to manufacture and supply 100% of EVO and EVO+ ICL lenses for China from Switzerland, eliminating tariff exposure.

Management Comments

• "The increase was primarily driven by strong sales performance in China, while distributor inventory was maintained at or below contractual levels."
• "EVO+ ICL carries a premium selling price, supporting potential margin expansion as production volumes increase over time."
• "As previously disclosed, shipments to the two distributors in China were largely suspended during the first half of 2025 due to elevated inventory levels following a market slowdown in 2024, with procedure demand primarily fulfilled from existing inventory."
• "Gross margin increased year-over-year to 73.6% from 65.8%, reflecting cost reduction initiatives implemented in the first quarter of 2025."
• "As production in Switzerland has scaled in 2026, unit costs have begun to improve."
• "Although cash and investments available for sale decreased to $163.9 million at April 3, 2026 from $187.5 million due to front-loaded payments for seasonal bonuses and other employee incentives, global sales meetings, severance, and costs associated with our Cooperation Agreement with Broadwood Partners, we expect to generate cash during the remainder of the year."

Industry Context

StockSavvy.ai notes that STAAR Surgical's strong performance, particularly in China, highlights the growing demand for advanced refractive surgery solutions like their ICLs. The company's ability to navigate supply chain and tariff challenges, while also focusing on manufacturing efficiencies, positions it well within the competitive ophthalmic device market.

Corporate Governance

Legal Proceedings

• The Company is involved in various legal proceedings and other matters arising in the normal course of business, including contractual rights and obligations, employment matters, and product liability claims. While no known claims are expected to have a material adverse effect, new or unexpected results could cause significant financial harm.

Related Party Transactions

• The Company paid $5,036,000 to Broadwood Partners, L.P. and $962,000 to Yunqi Capital for reimbursement of reasonable out-of-pocket fees and expenses incurred in connection with the merger with Alcon, as per the Cooperation Agreement. Both Broadwood and Yunqi Capital were holders of more than 5% of the Company's outstanding stock at the time of the agreement.

Stakeholder Impact

• Shareholders: The return to profitability and significant sales growth are positive indicators. The board changes may signal a shift in strategic direction or governance.
• Employees: Restructuring and severance costs were incurred, impacting workforce. Stock-based compensation remains a significant expense.
• Distributors: Strong sales growth in China suggests positive relationships, though inventory management remains a focus.
• Creditors: The company's liquidity appears sufficient for the next 12 months, with a positive working capital position.

Next Steps

• Continue to drive awareness and adoption of ICL procedures globally.
• Expand ICL product line availability in existing and new geographic markets.
• Provide surgeon training, support, and education, especially in newer markets.
• Manufacture and supply 100% of EVO and EVO+ ICL lenses for China from Switzerland by the end of fiscal 2026.

Key Dates

Recommendation

The company has demonstrated strong recovery and growth, particularly in its key markets, with improved profitability and margins. However, the decrease in cash reserves, ongoing merger-related costs, and inherent risks in the medical device sector warrant a cautious 'hold' rating until sustained performance and strategic clarity are further established.

Keywords

STAAR Surgical, 10-Q, Q1 2026, Implantable Collamer Lenses, ICL, EVO+, China sales, Financial Results, Ophthalmic Surgery, Refractive Surgery